Cargando…

Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España

INTRODUCTION: Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complication...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Rubio, Alberto, María Eiros, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159358/
https://www.ncbi.nlm.nih.gov/pubmed/29355006
_version_ 1783358614120955904
author Pérez-Rubio, Alberto
María Eiros, José
author_facet Pérez-Rubio, Alberto
María Eiros, José
author_sort Pérez-Rubio, Alberto
collection PubMed
description INTRODUCTION: Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complications, and the vaccine is officially recommended, as in the case of Spain, for certain risk groups, such as older people, chronic diseases and institutionalized population. The adjuvanted influenza vaccine with MF59, indicated for population over 65 years, has been shown to be more immunogenic than conventional influenza vaccines. The objective of this study is to assess the impact on the national and regional budget of the seasonal vaccination campaigns carried out in Spain using the MF59 adjuvanted vaccine compared to a conventional vaccine in a population older than 65 years. MATERIAL AND METHODS: We analyzed the budgetary impact of the use of the MF59-adjuvanted vaccine in the national territory and by Autonomous Communities through a modeling of two alternatives, conventional vaccination versus adjuvant vaccination with MF59 in a population older than 65 years. The cases of avoided influenza, avoided complications and avoided costs, as well as the economic impact of the vaccination program have been calculated. RESULTS: With the available information, the budgetary impact of using the influenza vaccine with MF59 in all the over 65 years, amounts to 6,967,288.10 €, avoiding for the national set a cost of 89.5 million Euros, which represents a potential savings of 82 million Euros and a cost-benefit ratio of 12.83. CONCLUSION: The use of the influenza vaccine with the MF59 adjuvant to all those over 65 years would mean an increase in the efficiency of the vaccination programs currently proposed in all the Autonomous Communities and in the Spanish state.
format Online
Article
Text
id pubmed-6159358
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-61593582018-10-03 Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España Pérez-Rubio, Alberto María Eiros, José Rev Esp Quimioter Original INTRODUCTION: Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complications, and the vaccine is officially recommended, as in the case of Spain, for certain risk groups, such as older people, chronic diseases and institutionalized population. The adjuvanted influenza vaccine with MF59, indicated for population over 65 years, has been shown to be more immunogenic than conventional influenza vaccines. The objective of this study is to assess the impact on the national and regional budget of the seasonal vaccination campaigns carried out in Spain using the MF59 adjuvanted vaccine compared to a conventional vaccine in a population older than 65 years. MATERIAL AND METHODS: We analyzed the budgetary impact of the use of the MF59-adjuvanted vaccine in the national territory and by Autonomous Communities through a modeling of two alternatives, conventional vaccination versus adjuvant vaccination with MF59 in a population older than 65 years. The cases of avoided influenza, avoided complications and avoided costs, as well as the economic impact of the vaccination program have been calculated. RESULTS: With the available information, the budgetary impact of using the influenza vaccine with MF59 in all the over 65 years, amounts to 6,967,288.10 €, avoiding for the national set a cost of 89.5 million Euros, which represents a potential savings of 82 million Euros and a cost-benefit ratio of 12.83. CONCLUSION: The use of the influenza vaccine with the MF59 adjuvant to all those over 65 years would mean an increase in the efficiency of the vaccination programs currently proposed in all the Autonomous Communities and in the Spanish state. Sociedad Española de Quimioterapia 2018-03-23 2018-02 /pmc/articles/PMC6159358/ /pubmed/29355006 Text en © The Author 2018 https://creativecommons.org/licenses/by-nc/4.0/ The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original
Pérez-Rubio, Alberto
María Eiros, José
Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title_full Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title_fullStr Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title_full_unstemmed Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title_short Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España
title_sort impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con mf59 en población mayor de 65 años en españa
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159358/
https://www.ncbi.nlm.nih.gov/pubmed/29355006
work_keys_str_mv AT perezrubioalberto impactoeconomicoysanitariodelautilizaciondevacunaantigripaladyuvadaconmf59enpoblacionmayorde65anosenespana
AT mariaeirosjose impactoeconomicoysanitariodelautilizaciondevacunaantigripaladyuvadaconmf59enpoblacionmayorde65anosenespana